Erratum: Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells (Oncogene (2012) 31 (4353-4361) DOI: 10.1038/onc.2011.627);Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells

Oncogene

Volumn 31, Issue 40, 2012, Pages 4353-4361

  Cutrupi, S ^a   Reineri, S ^a   Panetto, A ^a,b   Grosso, E ^a,c   Caizzi, L ^a   Ricci, L ^a,b   Friard, O ^a   Agati, S ^a   Scatolini, M ^c   Chiorino, G ^c   Lykkesfeldt, A E ^d   De Bortoli, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Bioindustry Park Silvano Fumero   (Italy)

^c Laboratory of Cancer Genomics   (Italy)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

breast cancer; estrogen receptor; Tab2; tamoxifen resistance

Indexed keywords

ADAPTOR PROTEIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; ESTROGEN RECEPTOR ALPHA; PROTEIN TAB2; RECOMBINANT INTERLEUKIN 1BETA; SMALL INTERFERING RNA; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PEPTIDE SYNTHESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TREATMENT RESPONSE;

EID: 84867233708     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.95     Document Type: Erratum

References (40)

1. Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG. (2002). Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 110: 55-67.
2. Broglie P, Matsumoto K, Akira S, Brautigan DL, Ninomiya-Tsuji J. (2010). Transforming growth factor beta-activated kinase 1 (TAK1) kinase adaptor, TAK1-binding protein 2, plays dual roles in TAK1 signaling by recruiting both an activator and an inhibitor of TAK1 kinase in tumor necrosis factor signaling pathway. J Biol Chem 285: 2333-2339.
3. Carroll JS, Lynch DK, Swarbrick A, Renoir JM, Sarcevic B, Daly RJ et al. (2003). p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res 63: 4322-4326.
4. Cicatiello L, Mutarelli M, Grober OM, Paris O, Ferraro L, Ravo M et al. (2010). Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol 176: 2113-2130.
5. Cicatiello L, Scafoglio C, Altucci L, Cancemi M, Natoli G, Facchiano A et al. (2004). A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol 32: 719-775.
6. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J et al. (2010). Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28: 509-518.
7. Early Breast Cancer Trialists' Collaborative Group (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
8. Frankel LB, Lykkesfeldt AE, Hansen JB, Stenvang J. (2007). Protein kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Breast Cancer Res Treat 104: 165-179.
9. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, Lykkesfeldt AE. (2005). Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 12: 599-614.
10. Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R et al. (2011). Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 29: 1657-1663.
11. Henriksen KL, Rasmussen BB, Lykkesfeld AE, Müller S, Ejlertsen B, Mouridsen HT. (2009). An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of advanced breast cancer. Acta Oncol 48: 522-531.
12. Hughes-Davies L, Caldas C, Wishart GC. (2009). Tamoxifen: the drug that came in from the cold. Br J Cancer 101: 875-878.
13. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP et al. (2005). Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23: 732-740.
14. Keeton EK, Brown M. (2005). Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19: 1543-1554.
15. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R et al. (1998). Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95: 2920-1925.
16. Lee YH, Bedford MT, Stallcup MR. (2001). Regulated recruitment of tumor suppressor BRCA1 to the p21 gene by coactivator methylation. Genes Dev 25: 176-188.
17. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM et al. (2008). Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9: 239.
18. Lykkesfeldt AE, Briand P. (1986). Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. Br J Cancer 53: 29-35.
19. Madsen MW, Reiter BE, Larsen SS, Briand P, Lykkesfeldt AE. (1997). Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 57: 585-589.
20. Mendoza H, Campbell DG, Burness K, Hastie J, Ronkina N, Shim JH et al. (2008). Roles for TAB1 in regulating the IL-1-dependent phosphorylation of the TAB3 regulatory subunit and activity of the TAK1 complex. Biochem J 409: 711-722.
21. Musgrove EA, Sutherland RL. (2009). Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643.
22. Nabha SM, Glaron S, Hong M, Lykkesfeldt AE, Schiff R, Osborne K et al. (2005). Upregulation of PKC-d contributes to antiestrogen resistance in mammary tumor cells. Oncogene 24: 3166-3176.
23. Ochsner SA, Steffen DL, Hilsenbeck SG, Chen ES, Watkins CM, McKenna NJ. (2009). GEMS (Gene Expression MetaSignatures), a web resource for querying meta-analysis of expression microarray datasets: 17b-estradiol in MCF-7 cells. Cancer Res 69: 23-26.
24. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA et al. (2003). Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353-361.
25. Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S et al. (2008). ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr Relat Cancer 15: 985-1002.
26. Patel LN, Zaro JL, Shen WC. (2007). Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res 24: 1977-1992.
27. Perissi V, Jepsen K, Glass CK, Rosenfeld MG. (2010). Deconstructing repression: evolving models of co-repressor action. Nat Rev Genet 11: 109-123.
28. Perissi V, Rosenfeld MG. (2005). Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 6: 542-554.
29. Privalsky ML. (2004). The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol 66: 315-360.
30. Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ et al. (2005). Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23: 94-101.
31. Sardi SP, Murtie J, Koirala S, Patten BA, Corfas G. (2006). Presenilindependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell 127: 185-197.
32. Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M et al. (2005). Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56Suppl 1: 10-20.
33. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA et al. (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95: 927-937.
34. Shin MS, Shinghirunnusorn P, Sugishima Y, Nishimura M, Suzuki S, Koizumi K et al. (2009). Cross interference with TNF-alphainduced TAK1 activation via EGFR-mediated p38 phosphorylation of TAK1-binding protein 1. Biochim Biophys Acta 1793: 1156-1164.
35. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H et al. (2004). Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935.
36. Smyth GK, Michaud J, Scott HS. (2005). Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21: 2067-2075.
37. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J et al. (2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
38. Takaesu G, Kishida S, Hiyama A, Yamaguchi K, Shibuya H, Irie K et al. (2000). TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell 5: 649-658.
39. Yue W, Fan P, Wang J, Li Y, Santen RJ. (2007). Mechanisms of acquired resistance to endocrine therapy in hormonedependent breast cancer cells. J Steroid Biochem Mol Biol 106: 102-110.
40. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H et al. (2006). Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124: 615-629.